HOLX News and Press, Hologic Inc. From 11/25/20

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 3 rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 p.m. Eastern Time. The presentation will be webcast live and may be accessed through a link on the investor...

This strategy exploits the anomaly that equities perform best from November to April, and less so from May to October during most years. ETFs (XLV, XLI, XLY, XLB) have historically performed best from November to April, and ETFs (XLK, XLP, XLU, QQQ) have done better than the first gro...

The FDA has approved Hologic's (HOLX) diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring assay.The Aptima HIV-1 Quant Dx assay, a molecular diagnostic test that runs on the fully automated, sample-to-result Panther system is now the first dual-clai...

-- First FDA-Approved Assay for Both Qualitative Diagnosis and Quantitative Viral Load Monitoring -- Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved a diagnostic claim for its HIV-1 (human immunodeficiency virus type...

The FDA has issued an emergency use authorization ((EUA)) to the single-use COVID-19 diagnostic test kit from Lucira Health, a California manufacturer.The Lucira COVID-19 All-In-One at home test kit provides rapid results. To date, the Agency has authorized nearly 300 test...

Hologic has had a stellar 2020 on the back of servicing enormous global Covid-19 testing volumes, and contract manufacturing agreements have just been extended to 2021. Management has updated guidance for 2021, where Covid testing revenues will widen the capital allocation potential i...

The sellers of diagnostic tests for SARS-CoV-2 and antibodies to the coronavirus are under early pressure in apparent reaction to positive interim data on Pfizer and BioNTech's COVID-19 vaccine that showed 90% efficacy. An effective vaccine, when widely deployed, will imply reduced testing de...

Biogen BIIB -28% after FDA advisory committee snub of Alzheimer’s drug.Quidel (QDEL) -26%.HighPoint Resources HPR -25% on Q3 earnings release.Co-Diagnostics CODX -24%.Enlivex Therapeutics (ENLV) -21%.Liquidia Technologies LQDA -20% on Q3 earnings...

Kahn Brothers’ 13F portfolio value decreased from $592M to $528M this quarter. Patterson-UTI was increased while reducing Merck, Seaboard, Sterling Bancorp, and Hologic. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 1...

Palm Beach, FL – November 5, 2020 – Covid-19 tests are critical in the management of the ongoing COVID-19 pandemic for accurate diagnosis as well as for tackling the spread of the infection. Over 600 SARS-CoV-2 diagnostic tests are either approved or are in the development pha...